Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in Thrombotic Microangiopathy
NCT00726544Phase 2Terminated
- Sponsor
- Archemix Corp.
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- RNA Aptamers, Recombinant Proteins and Enzymes, DNA Aptamers
- Countries
- 5
01
Overview
A Phase 2 trial of egaptivon pegol in thrombotic microangiopathy (TMA), thrombotic thrombocytopenic purpura (TTP), sponsored by Archemix Corp.. Started Dec 2008; status: terminated.
02
Drugs
egaptivon pegol
03
Conditions
thrombotic microangiopathy (TMA)thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT00726544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726544.